Abstract
Background
Gastroesophageal reflux disease (GERD) is considered the main etiologic process in the metaplastic development of Barrett’s esophagus (BE). The most serious complication of BE is the possible dysplastic evolution to esophageal carcinoma. Many treatments have been described to prevent the progression of BE. The outcomes of these interventions are controversial. The aim of this study was to assess whether laparoscopic fundoplication for GERD had an impact on the development of BE.
Methods
Prospective data were collected from patients who were treated with a laparoscopic fundoplication for BE. Data was collected and analyzed for a variety of clinical and pathologic outcomes.
Results
Laparoscopic fundoplications were completed between 1993 and 2001, with a total sample size of 92 (mean age 53 ± 11.8 years). Each patient was diagnosed with GERD associated with BE confirmed by both endoscopy and biopsy. A laparoscopic fundoplication was performed in all patients (360° fundoplication in 81 patients and partial fundoplication in 11 patients). There was no postoperative mortality or major complications from the procedure. The mean postoperative stay was 3 ± 1 days. Seventy patients (76% of the overall sample size) were followed up for a mean 4.2 ± 2.6 years. Of the patients available for follow-up, 33% (n = 23) had a complete regression of their BE; 21% (n = 15) had a decrease in the degree of metaplasia/dysplasia; 39% (n = 27) had no significant change; and 7% (n = 5) experienced a progression of the BE. Five patients required further procedures for three reasons: (1) GERD recurrence (n = 2), (2) progression of BE (n = 2), and (3) intrathoracic migration (n = 1). No patients developed high-grade dysplasia or esophageal carcinoma.
Conclusions
The results of this study suggest that laparoscopic fundoplication offers a safe and effective long-term treatment for BE. The procedure also demonstrated regression of BE in more than 50% of the sample size.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbas AE, Deschamps C, Cassivi SD, Allen MS, Nichols FC, Miller DL, Pairolero PC (2004) Barrett’s esophagus: the role of laparoscopic fundoplication. Ann Thor Surg 77: 393–396
Attwood SE (1993) Barrett’s esophagus. Curr Opin Gen Surg 180–188
Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ (2002) Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 97: 1930–1936
Corey KE, Schmitz SM, Shaheen NJ (2003) Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 98: 2390–2394
Csendes A (2004) Surgical treatment of Barrett’s esophagus: 1980–2003. World J Surg 28: 225–231
Csendes A, Burdiles P Braghetto I, Smok G, Castro G, Korn O, Henriquez A (2002) Dysplasia and adenocarcinoma after classical antireflux surgery in patients with Barrett’s esophagis: the need for long-term a subjective and objective follow-up. Ann Surg 235: 178–185
Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, Henriquez A (2002) Clinical, endoscopic, and functional studies in 408 patients with Barrett’s esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 97:554–560
DeMeester SR (1997). Management of Barrett’s esophagus free of dysplasia. Semin Thorac Cardiovasc Surg 9: 279–284
DeMeester SR, Campos GM, DEMeester TR, Bremner CG, Hagen JA, Peters JH, Crookes PF (1998) The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 228:547–556
DeMeester SR, DeMeester TR (1999) The diagnosis and management of Barrett’s esophagus. Adv Surg 33: 29–68
Desai KM, Soper NJ, Frisella MM, Quasebarth MA, Dunnegan DL, Brunt LM (2003) Efficacy of laparoscopic antireflux surgery in patients with Barrett’s esophagus. Am J Surg 186: 652–659
Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Flijou JF (2004) Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high grade dysplasia in Barrett’s esophagus. Gastrointest Endosc 59: 880–889
Fass R, Hell RW, Garewal HS, Martinez P, Pulliam G, Wendel C, Sampliner RE (2001) Correlation of oesophageal acid exposure with Barrett’s oesophagus length. Gut 48: 310–313
Gurski R, Peters J, Hagen J, DeMeester SR, Bremner CG, Chandrasoma PT, DeMeester TR (2003) Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 196: 706–712
Horwath JD, Baroni D, Maydonovitch C (2001) The incidence of regression and normalization of intestinal metaplasia in a cohort of patients with EGJSIM, SSBE and LSBE followed over 3 years. Gastroenterology 118: A224
O’Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV (2004) Long-term clinical and pathologic response of Barrett’s esophagus after antireflux surgery. Am J Surg 188: 27–33
Parilla P, Martinez de Haro L, Ortiz A, Munitiz V, Molina J, Bermejo J Canteras M (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237: 291–298
Sampliner RE, (2003) Prevention of adenocarcinoma by reversing Barrett’s esophagus with mucosal ablation. World J Surg 27:1026–1029
Tigges H, Fuchs KH, Maroske J, Freys SM, Muller J, Thiede A (2001) Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett’s esophagus. J Gastrointest Surg 5: 251–259
van Blankenstein M (2002) Barrett’s esophagus: so what! Dis Esophagus 15: 1–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Biertho, L., Dallemagne, B., Dewandre, JM. et al. Laparoscopic treatment of Barrett’s esophagus: long-term results. Surg Endosc 21, 11–15 (2007). https://doi.org/10.1007/s00464-005-0023-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-005-0023-y